Login / Signup

Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants.

Eunice StiboyMei ChanMd Saiful IslamGemma L SaravanosKei LuiAdam JaffeNusrat Homaira
Published in: Pediatric pulmonology (2023)
Standardisation of CPGs may improve clinical decision making around use of palivizumab in high-risk infants. This article is protected by copyright. All rights reserved.
Keyphrases
  • respiratory syncytial virus
  • decision making
  • sars cov
  • respiratory tract
  • early onset
  • drug induced